Pharmacokinetic assessment of ketanserin in the horse.

The research studies the movement and effects of the drug ketanserin in horses, with the researchers using a computer model to optimize dosage. The conclusions were reached using both single and multiple doses.

Study Objective

• The primary objective of this study involved understanding the pharmacokinetics, that is, the movement of the drug ketanserin, within the body of a healthy horse. The scientists aimed to create a mathematical model that would aid in determining optimal dosage.

Methods Used

• The researchers measured plasma concentrations of ketanserin in the horses’ blood, utilizing liquid chromatography coupled with mass spectrometry. This approach was applied following both single and multiple intravenous applications.

Findings

• Upon reviewing the concentration-time profile for plasma levels of ketanserin, a two-compartment linear pharmacokinetic model was found to best represent the data, following single and consecutive doses in healthy horses.
• Various pharmacokinetic parameters were identified, including an 11.5-hour terminal half-life for ketanserin, a steady-state volume of distribution at 10.5L/kg, and clearance at a rate of 0.87 L/h/kg.
• The study also identified the Area Under the Curve (AUC – a metric representing total drug exposure over time) as 115 ng·h/mL – a value that stands out when assessing the drug’s overall exposure.

Simulations and Validation

• An examination of three healthy horses suggested a dose of 0.3 mg/kg given every 8 hours was apt. This was established based on linear pharmacokinetics in the horses sampled and offered a stable systemic blood concentration of the drug over 3 ng/mL. Thus, a predictive model was created for vet practitioners to employ this drug effectively.

It’s important to note, however, that these findings are based on a small sample size, and more extensive studies are necessary for better substantiation.